AU2002223703A1 - Prevention of development of dyskinesias - Google Patents

Prevention of development of dyskinesias

Info

Publication number
AU2002223703A1
AU2002223703A1 AU2002223703A AU2370302A AU2002223703A1 AU 2002223703 A1 AU2002223703 A1 AU 2002223703A1 AU 2002223703 A AU2002223703 A AU 2002223703A AU 2370302 A AU2370302 A AU 2370302A AU 2002223703 A1 AU2002223703 A1 AU 2002223703A1
Authority
AU
Australia
Prior art keywords
prevention
development
dyskinesias
alfa2
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223703A
Inventor
Antti Haapalinna
Juuso Juhila
Jouni Sirvio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of AU2002223703A1 publication Critical patent/AU2002223703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

The present invention relates to the prevention of the development of sensitization caused by chronic use of dopaminergic agents using an alfa2-adrenoceptor antagonist or a pharmaceutically acceptable ester or salt thereof.
AU2002223703A 2000-11-14 2001-11-13 Prevention of development of dyskinesias Abandoned AU2002223703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24800400P 2000-11-14 2000-11-14
US60/248,004 2000-11-14
PCT/FI2001/000989 WO2002039991A2 (en) 2000-11-14 2001-11-13 Prevention of development of dyskinesias

Publications (1)

Publication Number Publication Date
AU2002223703A1 true AU2002223703A1 (en) 2002-05-27

Family

ID=22937245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223703A Abandoned AU2002223703A1 (en) 2000-11-14 2001-11-13 Prevention of development of dyskinesias

Country Status (8)

Country Link
US (2) US20040039041A1 (en)
EP (1) EP1333828B1 (en)
JP (1) JP2004513917A (en)
AT (1) ATE399548T1 (en)
AU (1) AU2002223703A1 (en)
CA (1) CA2428603C (en)
DE (1) DE60134659D1 (en)
WO (1) WO2002039991A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430328A1 (en) * 2001-09-28 2003-04-10 Kyowa Hakko Kogyo Co., Ltd. Receptor antagonist
FI20022007A0 (en) 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromucosal preparation and method of preparation thereof
WO2005066357A1 (en) * 2004-01-05 2005-07-21 Mitsubishi Pharma Corporation Method of screening molecule associated with psychiatric disorder
WO2016104367A1 (en) * 2014-12-22 2016-06-30 株式会社Ｌｔｔバイオファーマ Functional dyspepsia therapeutic drug

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2706303B1 (en) * 1993-06-18 1995-09-08 Pf Medicament Use of Efaroxan and its derivatives for the preparation of a medicament intended for the treatment of Parkinson's disease.
FR2759291A1 (en) * 1997-02-13 1998-08-14 Pf Medicament PRODUCT CONTAINING IDAZOXAN AND 1-DOPA AS A COMBINED PHARMACEUTICAL PREPARATION FOR PARKINSON'S DISEASE
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine

Also Published As

Publication number Publication date
DE60134659D1 (en) 2008-08-14
CA2428603C (en) 2010-06-22
US20020115703A1 (en) 2002-08-22
CA2428603A1 (en) 2002-05-23
WO2002039991A3 (en) 2002-08-29
ATE399548T1 (en) 2008-07-15
US20040039041A1 (en) 2004-02-26
WO2002039991A2 (en) 2002-05-23
JP2004513917A (en) 2004-05-13
EP1333828A2 (en) 2003-08-13
EP1333828B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
DK1663229T3 (en) Pharmaceutical combinations of hydrocodone and naltrexone
MXPA06000675A (en) Quinolone derivative or salt thereof.
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ATE297203T1 (en) ANTITHRBOTIC AGENTS
DE69831868D1 (en) Antithrombosemittel
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
CY1108725T1 (en) Combination of NMDA antagonist and acetylcholinesterase inhibitors for the treatment of ALZHEIMER
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
DK1416842T3 (en) Pharmaceutical combinations of oxycodone and naloxone
TR200100432T2 (en) Hepatitis C inhibitor tri-peptides
IS6069A (en) N-cyanomethylamide as protease inhibitor
BG106585A (en) Kinase inhibitors as therapeutic agents
TNSN06138A1 (en) INHIBITORS OF THE MUTANT FORM OF KIT
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
TNSN06220A1 (en) Benzimidazole derivatives
BR0211972A (en) Ophthalmic Composition
AU2003239389A1 (en) Opioid receptor antagonists
IT1302682B1 (en) ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORPHINE
BR0314844A (en) New compound
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
DE60114640D1 (en) Antithrombosemittel
AU2002223703A1 (en) Prevention of development of dyskinesias
EE05241B1 (en) Use of the α-halogenoacryl derivative of distamycin